» Articles » PMID: 24411627

Radiation Therapy Administration and Survival in Stage I/II Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue

Overview
Specialties Oncology
Radiology
Date 2014 Jan 14
PMID 24411627
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To determine the factors associated with the use of radiation therapy and associated survival outcomes in early-stage marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT).

Methods And Materials: We extracted data on adult patients with stage I/II MALT lymphoma diagnoses between 1998 and 2010 recorded in the Surveillance, Epidemiology, and End Results (SEER) database. We studied factors associated with radiation therapy administration in a logistic regression model and described the cumulative incidence of lymphoma-related death (LRD) according to receipt of the treatment. The association of radiation therapy with survival was explored in multivariate models with adjustment for immortal time bias.

Results: Of the 7774 identified patients, 36% received radiation therapy as part of the initial course of treatment. Older patients; black or Hispanic men; white, Hispanic, and black women; and socioeconomically disadvantaged and underinsured patients had a significantly lower chance of receiving radiation therapy. Radiation therapy administration was associated with a lower chance of LRD in most sites. In cutaneous, ocular, and salivary MALT lymphomas, the 5-year estimate of LRD after radiation therapy was 0%. The association of radiation therapy with overall survival in different lymphoma sites was heterogeneous, and statistically significant in cutaneous (hazard ratio 0.45, P=.009) and ocular (hazard ratio 0.47, P<.0001) locations after multivariate adjustment.

Conclusions: Demographic factors are associated with the use of radiation therapy in MALT lymphoma. Clinicians should be sensitive to those disparities because the administration of radiation therapy may be associated with improved survival, particularly in cutaneous and ocular lymphomas.

Citing Articles

Treatment and survival for patients with localized primary ocular adnexal extranodal marginal zone lymphoma.

Gao L, Li X, Wang X, Liang Y, Wu Y, Feng X Leukemia. 2024; 38(4):914-917.

PMID: 38503872 DOI: 10.1038/s41375-024-02227-5.


Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas.

Alhaj Moustafa M, Borah B, Moriarty J, Dholakia R, Jiang L, Li K Clin Lymphoma Myeloma Leuk. 2023; 23(4):259-265.

PMID: 36775698 PMC: 11402514. DOI: 10.1016/j.clml.2023.01.010.


Predictors of survival in patients with MALT lymphoma: a retrospective, case-control study.

Qi S, Liu X, Noy A, Lee J, Teckie S, Hajj C Blood Adv. 2022; 7(8):1496-1506.

PMID: 36399527 PMC: 10125910. DOI: 10.1182/bloodadvances.2022007772.


An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.

Alderuccio J, Arcaini L, Watkins M, Beaven A, Shouse G, Epperla N Blood Adv. 2022; 6(7):2035-2044.

PMID: 35196377 PMC: 9006265. DOI: 10.1182/bloodadvances.2021006844.


The use of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography integrated with computed tomography for accurate staging and surveillance in the case of mucosa-associated lymphoid tissue.

Zhang S, Rossetti-Chung A, Sood S, Terezakis S J Radiol Case Rep. 2021; 15(3):19-28.

PMID: 34267867 PMC: 8253150. DOI: 10.3941/jrcr.v15i3.4193.